Spinal Cord Injury Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Spinal Cord Injury market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as NervGen Pharma, StemCells, Inc., Kringle Pharma, Inc., Kessler Foundation, Mitsubishi Tanabe Pharma America Inc., Moleac Pte Ltd., Vertex Pharmaceuticals Incorporated, KAI Pharmaceuticals, Lineage Cell Therapeutics, Inc. Sanofi, AbbVie, ReNetX Bio, Inc., Neuroplast, Daiichi Sankyo, Eli Lilly and Company, Neurofix S.L., Acorda Therapeutics, Bayer, RDD Pharma Ltd, Acorda Therapeutics, Bayer

[Nevada, United States] - DelveInsight's "Spinal Cord Injury Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Spinal Cord Injury, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Spinal Cord Injury Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Spinal Cord Injury Market Report:
• The Spinal Cord Injury market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
• In September, 2024: S.Biomedics Co., Ltd. announced that their study intends to evaluate the safety and exploratory efficacy of transplantation therapy using neural precursor cells (PSA-NCAM(+) NPC) derived from the human embryonic stem cell line for the treatment of paralysis and other related symptoms from sub-acute spinal cord injury.
• In July, 2024: Mitsubishi Tanabe Pharma America Inc. announced that the purpose of their study is to compare the efficacy and safety of intravenous (IV) infusions of MT-3921 to placebo in subjects with acute traumatic cervical spinal cord injury.
• In July, 2024:Urovant Sciences GmbH announced that the purpose of their study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC
• In June, 2024: AbbVie announced that Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration.
• According to WHO (2024), globally, over 15 million people are living with spinal cord injury
• As per Bennett et al. (2022), in the United States, there are approximately 17,000 new cases of SCI each year, and roughly 282,000 persons are estimated to be living with SCI
• According to WHO (2024), SCI is a major cause of long-term disability, accounting for over 4.5 million years of life lived with disability (YLDs) in 2021
• As per the Japanese National Spinal Cord Injury Database, from 1997 until 2019, 5,569 spinal cord injury cases were registered into a database, and the percentage of female patients affected by SCI is estimated to be between 10 and 20 percent
• Key Spinal Cord Injury Companies are as follows: NervGen Pharma, StemCells, Inc., Kringle Pharma, Inc., Kessler Foundation, Mitsubishi Tanabe Pharma America Inc., Moleac Pte Ltd., Vertex Pharmaceuticals Incorporated, KAI Pharmaceuticals, Lineage Cell Therapeutics, Inc. Sanofi, AbbVie, ReNetX Bio, Inc., Neuroplast, Daiichi Sankyo, Eli Lilly and Company, Neurofix S.L., Acorda Therapeutics, Bayer, RDD Pharma Ltd, Acorda Therapeutics, Bayer
• Key Spinal Cord Injury Therapies are as follow: NVG-291, HuCNS-SC cells, KP-100IT, Dalfampridine:, MT-3921, NeuroAiD, Cethrin, KAI-1678, AST-OPC1, HP184, Elezanumab, AXER-204, Neuro-Cells, SUN13837, tadalafil, NFX88, Fampridine-SR, Vardenafil, Oxymetazoline, Fampridine, Levitra
• Launching multiple stage Spinal Cord Injury pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Spinal Cord Injury market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Spinal Cord Injury Overview:
Spinal Cord Injury (SCI) refers to damage to the spinal cord resulting from trauma or non-traumatic causes like tumors, degenerative and vascular conditions, infections, toxins or birth defects

Spinal Cord Injury Epidemiology Segmentation:
The Spinal Cord Injury market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Spinal Cord Injury Total cases
• Spinal Cord Injury Diagnosed Cases
• Spinal Cord Injury Gender-specific Cases
• Spinal Cord Injury Cause-specific Cases

For more information about Spinal Cord Injury companies working in the treatment market, visit https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Spinal Cord Injury Market Insights
• Many therapeutic strategies have been proposed to overcome neurodegenerative events and reduce secondary neuronal damage. Efforts have also been devoted in developing neuroprotective and neuro-regenerative therapies that promote neuronal recovery and outcome
• Each year, various research activities are being carried out to understand the disease and develop suitable therapeutic molecule so that a more concrete treatment approachcan be developed for the SCI patients
• Increasing cases of SCI in various regions lead to increased demand for advanced diagnostic and treatment from this market, which in turn contribute to the growth of the market

Spinal Cord Injury Drugs Uptake
• KP-100IT is an HGF that has been shown to exhibit a wide variety of physiological activities, not only as a mitogenic factor for liver cells but also as mitogenic, anti-apoptotic (cell death), morphogenic, and angiogenic factors for various other types of cells
• NEURO-CELLS are derived from the bone marrow of the patient itself. The company's technology calls on the self-healing capacity of non-manipulated stem cells, that the body itself is unable to leverage for neurodegenerative conditions due to the blood brain barrier.
• NVG-291, a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair. NVG-291 is derived from the intracellular wedge domain of the receptor type protein tyrosine phosphatase sigma (PTPσ).

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Spinal Cord Injury Therapies and Key Companies:
• NVG-291: NervGen Pharma
• HuCNS-SC cells: StemCells, Inc.
• KP-100IT: Kringle Pharma, Inc.
• Dalfampridine: Kessler Foundation
• MT-3921: Mitsubishi Tanabe Pharma America Inc.
• NeuroAiD: Moleac Pte Ltd.
• Cethrin: Vertex Pharmaceuticals Incorporated
• KAI-1678: KAI Pharmaceuticals
• AST-OPC1: Lineage Cell Therapeutics, Inc.
• HP184: Sanofi
• Elezanumab: AbbVie
• AXER-204: ReNetX Bio, Inc.
• Neuro-Cells: Neuroplast
• SUN13837: Daiichi Sankyo
• tadalafil: Eli Lilly and Company
• NFX88: Neurofix S.L.
• Fampridine-SR: Acorda Therapeutics
• Vardenafil: Bayer
• Oxymetazoline: RDD Pharma Ltd
• Fampridine: Acorda Therapeutics
• Levitra: Bayer

Spinal Cord Injury Epidemiology:
The Spinal Cord Injury epidemiology section provides insights into the historical and current Spinal Cord Injury patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool, its trends, and assumptions undertaken.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Spinal Cord Injury Market Drivers:
• Both universities and industries are coming up with better approaches aiming towards development of a novel therapy
• Advances in understanding of SCI pathophysiology over recent years has however led to a surge of clinical trials
• Recent continuous efforts in basic and clinical research are creating new path to regenerative medicine for SCI
• Absence of an effective therapy targeting symptoms and complications associated with SCI

Spinal Cord Injury Market Barriers:
• Researchers are still apprehensive and cynical about the viability for stem cell therapies
• Pricing and market access remain a major bone of contention
• A large number of clinical trials have failed to achieve desired results which could be attributed to unknown etiology of disease and poor trial design
• Early approval of stem cell based treatments allow patients to take experimental therapies that could be ineffective or dangerous, at a high cost to both patients and insurance providers

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Spinal Cord Injury Market Report:
• Study Period: 2019-2032
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Spinal Cord Injury Companies: NervGen Pharma, StemCells, Inc., Kringle Pharma, Inc., Kessler Foundation, Mitsubishi Tanabe Pharma America Inc., Moleac Pte Ltd., Vertex Pharmaceuticals Incorporated, KAI Pharmaceuticals, Lineage Cell Therapeutics, Inc. Sanofi, AbbVie, ReNetX Bio, Inc., Neuroplast, Daiichi Sankyo, Eli Lilly and Company, Neurofix S.L., Acorda Therapeutics, Bayer, RDD Pharma Ltd, Acorda Therapeutics, Bayer
• Key Spinal Cord Injury Therapies: NVG-291, HuCNS-SC cells, KP-100IT, Dalfampridine:, MT-3921, NeuroAiD, Cethrin, KAI-1678, AST-OPC1, HP184, Elezanumab, AXER-204, Neuro-Cells, SUN13837, tadalafil, NFX88, Fampridine-SR, Vardenafil, Oxymetazoline, Fampridine, Levitra
• Spinal Cord Injury Therapeutic Assessment: Current marketed and emerging therapies
• Spinal Cord Injury Market Dynamics: Spinal Cord Injury Market drivers and Spinal Cord Injury barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Spinal Cord Injury Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Spinal Cord Injury market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/spinal-cord-injury-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Spinal Cord Injury Market Overview at a Glance
4. Key Events
5. Spinal Cord Injury Epidemiology and Market Methodology
6. Executive Summary of Spinal Cord Injury
7. Disease Background and Overview
8. Spinal Cord Injury Epidemiology and Patient Population
9. Spinal Cord Injury Marketed Therapies
10. Emerging Spinal Cord Injury Therapies
11. Spinal Cord Injury Patient Journey
12. Spinal Cord Injury: 7MM Analysis
13. The United States: Spinal Cord Injury Market Size
14. EU4 and the UK: Spinal Cord Injury Market Size
15. Japan: Spinal Cord Injury Market Size
16. Spinal Cord Injury Market Access and Reimbursement
17. Unmet Needs
18. SWOT Analysis
19. Spinal Cord Injury KOL Views
20. Appendix
21. DelveInsight's Capabilities
22. Disclaimer
23. About DelveInsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.